



Drug Coverage Policy

Effective Date.....6/15/2026

Coverage Policy Number.....IP0806

Policy Title.....Edaravone Intravenous

Neurology –Edaravone Intravenous

- Radicava® (edaravone intravenous infusion – Mitsubishi Tanabe, generic)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

OVERVIEW

Edaravone intravenous (IV) is indicated for the treatment of **amyotrophic lateral sclerosis (ALS)**.¹

Edaravone IV is an anti-oxidative, free radical scavenger which eliminates lipid peroxide and hydroxyl radicals; however, it is unknown exactly how edaravone IV exerts its therapeutic effect in ALS.^{1,2}

Page 1 of 7

Coverage Policy Number: IP0806

Of note, Radicava ORS[®] (edaravone oral suspension) is indicated for the treatment of ALS.¹ Radicava ORS received FDA-approval under the 505(b)(2) approval pathway which relied upon evaluations of safety and efficacy for edaravone IV. Patients treated with edaravone IV may be switched to Radicava ORS using the same dosing frequency.

Clinical Efficacy

The efficacy of edaravone IV was evaluated in one Phase III, randomized, double-blind, placebo-controlled trial conducted in Japan called Study 19 (published) [n = 137].² This study enrolled patients who had a “definite” or “probable” diagnosis of ALS (based on El Escorial and revised Airlie House criteria; criteria provided in the Appendix) and were living independently at the time of screening. Patients also were required to have functionally retained most activities of daily living (defined as a score of two points or better on each individual item of the ALS Functional Rating Scale – Revised [ALSFRS-R]), have normal respiratory function (i.e., a percent-predicted forced vital capacity [FVC] value \geq 80%), and have a disease duration of \leq 2 years. Overall, 91% of patients were also receiving riluzole. The decline in the ALSFRS-R scores from baseline to Week 24 was statistically significantly less with edaravone IV compared with placebo.^{1,2} In a separate study involving patients with longer disease duration, reduced respiratory function, and less certain ALS diagnosis, edaravone IV did not demonstrate benefit vs. placebo.³

A post hoc analysis of Study 19 compared the efficacy of edaravone at Week 48 in patients with FVC \geq 80% vs. patients with FVC $<$ 80%.¹⁵ Patients in both groups had a reduction in the ALSFRS-R score loss vs. placebo patients through Week 48. The treatment difference between edaravone-edaravone vs. placebo-edaravone in patients with FVC \geq 80% and FVC $<$ 80% was 2.05 and 4.94, respectively, which were both statistically significant.

Guidelines

The American Academy of Neurology practice parameter on the care of patients with ALS (last updated 2009; reaffirmed 2023) does not yet address edaravone IV.^{4,5} The practice parameter states that riluzole is safe and effective for slowing disease progression to a modest degree and should be offered to patients with ALS. However, riluzole may result in fatigue in some patients and if the risk of fatigue outweighs the modest survival benefits, discontinuation of riluzole may be considered. Referral to a specialized multidisciplinary clinic should be considered for patients with ALS to optimize health care delivery, prolong survival, and enhance quality of life. Additionally, noninvasive mechanical ventilation may lengthen survival and can be considered to improve quality of life and slow FVC decline. The European Federation of Neurological Societies guidelines on the clinical management of ALS (2012) also recommend patients be offered treatment with riluzole as early as possible after diagnosis.⁶ However, patients with progressive muscular atrophy, primary lateral sclerosis, or hereditary spastic paraplegia should not be treated with riluzole. The European Academy of Neurology guideline on the management of ALS, in collaboration with the European Reference Network of Neuromuscular Diseases (2024), does not recommend the use of IV or oral Radicava outside the context of a clinical trial.¹⁴ The interim recommendation states that the evidence will be reviewed and the recommendation will be updated, once the results from the ongoing Phase III trial of oral Radicava in Europe are available.

Coverage Policy

Policy Statement

Prior Authorization is required for benefit coverage of edaravone IV. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted

below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with edaravone IV as well as the monitoring required for adverse events and long-term efficacy, approval requires edaravone IV to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Edaravone IV is considered medically necessary when the following are met:

FDA-Approved Indication

1. Amyotrophic Lateral Sclerosis (ALS). Approve for 6 months if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve if the patient meets ALL of the following (i, ii, iii, iv, and v):

i. According to the prescriber, the patient has a “definite” or “probable” diagnosis of amyotrophic lateral sclerosis (ALS) based on the application of the El Escorial or the revised Airlie House diagnostic criteria; AND

ii. Patient has a score of two points or more on each item of the ALS Functional Rating Scale – Revised (ALSFRS-R) [i.e., has retained most or all activities of daily living]; AND

iii. According to the prescriber, patient has adequate respiratory function and does not require invasive ventilation; AND

iv. Patient has received or is currently receiving a riluzole product; AND

Note: Examples of riluzole products include riluzole tablets, Tiglutik (riluzole oral suspension), Teglutik (riluzole oral suspension), or Exservan (riluzole oral film).

v. The medication is prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS; OR

B) Patient is Currently Receiving Edaravone IV, Radicava IV, or Radicava ORS. Approve if the patient meets ALL of the following (i, ii, and iii):

i. Patient does not require invasive ventilation; AND

ii. According to the prescriber, the patient continues to benefit from therapy; AND

iii. The medication is prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS.

Dosing. Approve the following dosing regimens (A and B):

A. 60 mg intravenous infusion once daily; AND

B. Treatment Cycles:

i. Initial Cycle: Administer for 14 days followed by a 14-day drug-free period.

ii. Subsequent cycles: Administer for 10 days out of a 14-day period, followed by a 14-day drug-free period.

Conditions Not Covered

Edaravone IV for any other use is considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as newly published data are available):

1. Aneurysmal Subarachnoid Hemorrhage. Edaravone IV is not indicated for the treatment of aneurysmal subarachnoid hemorrhage (SAH).¹ One randomized controlled study (published) [n = 91] evaluated the efficacy of edaravone (formulation/dose not specified) in patients with aneurysmal SAH.⁷ At 3 months post-SAH, the incidence of delayed ischemic neurologic deficits (DINDs) in patients treated with edaravone was 10% vs. 21% in patients in a control group; the between-group treatment difference was not significant. In patients who had DINDs, 66% of patients in the control group had a cerebral infarction caused by

vasospasm compared with 0% of edaravone -treated patients ($P = 0.028$). Additional, well-designed clinical studies are needed to establish if edaravone has a role in therapy post-SAH.

- 2. Myocardial Infarction.** Edaravone IV is not indicated for the treatment of myocardial infarction; there are no US or North American studies of edaravone IV for this indication.¹ One randomized, placebo-controlled, open-label, Japanese study (published) [$n = 101$] evaluated the effect of edaravone IV on the long-term prognosis in patients experiencing an acute myocardial infarction.⁸ Patients were randomized to receive either edaravone IV (non-US formulation) 30 mg or placebo immediately prior to reperfusion. In all patients, successful reperfusion was obtained within 6 hours post-symptom onset. Edaravone IV significantly attenuated the infarct size and incidence of reperfusion arrhythmia compared with placebo ($P = 0.035$ and $P = 0.031$, respectively).
- 3. Radiation-Induced Brain Injury.** Edaravone IV is not indicated for the treatment of radiation-induced brain injury; there are no US or North American studies of edaravone IV for this indication.¹ One randomized, open-label, 3-month, Chinese study (published) [$n = 137$] evaluated the protective effect of edaravone IV on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma.⁹ Patients were randomized to receive edaravone IV (non-US formulation) 30 mg twice daily for 2 weeks (not FDA-approved dosing) + IV corticosteroid therapy or placebo + IV corticosteroid therapy. Following 3 months of therapy, radiologic improvement (reduction in edema of $\geq 25\%$) was observed in 55.6% of patients who received edaravone IV ($n = 40/72$) compared with 35.4% of patients treated with placebo ($n = 23/65$) [$P = 0.025$]. The area of T1-weighted contrast enhancement was reduced from baseline with both edaravone IV and placebo (-1.67 cm and -1.20 cm, respectively); however, the difference between the treatment arms was not statistically significant. Improvement in neurologic signs and symptoms evaluated by the Late Effects of Normal Tissues – Subjective, Objective, Management, Analytic (LENT/SOMA) scale was also observed in 61.1% of edaravone IV-treated patients vs. 38.5% of placebo-treated patients ($P = 0.006$). Further research is warranted to determine if edaravone IV has a place in therapy in the treatment of radiation-induced brain injury.
- 4. Retinal Vein Occlusion.** Edaravone IV is not indicated for the prevention of macular edema and improvement of visual acuity after arteriovenous sheathotomy in patients with branch retinal vein occlusion; there are no US or North American studies of edaravone IV for this indication.¹ A single, small, prospective, Japanese study [published] ($n = 47$) evaluated the efficacy of edaravone IV (non-US formulation) in patients with branch retinal vein occlusion undergoing vitrectomy.¹⁰ Patients either received edaravone IV 30 mg at the time of the procedure or no additional therapy. Visual acuity was measured before and 12 months after the procedure. At 12 months following the operation, the logarithm of the minimum angle of resolution (logMAR) units improved from 0.22 to 0.56 logMAR units in patients who had received edaravone IV and from 0.20 to 0.27 logMAR units in patients who did not receive active treatment ($P = 0.016$). Additional data are needed to support the use of edaravone IV for this indication.
- 5. Sensorineural Hearing Loss.** Edaravone IV is not indicated for the treatment of sensorineural hearing loss; there are no US-based studies of edaravone IV for this indication.¹ One small, Japanese study evaluated 14 patients with idiopathic sudden sensorineural hearing loss treated with edaravone IV (non-US formulation; dose not specified).¹¹ These patients were compared with a control group of 14 patients with similar prognostic factors who had been treated with hyperbaric oxygenation therapy. No significant differences were observed between the edaravone IV group and the control group.

6. Stroke. Eदारavone IV is not FDA-approved for the treatment of patients who have experienced stroke.¹ Eदारavone IV has been approved in other countries for this indication and there are some non-US data supporting its use.¹² There are no US-based studies of edaravone IV for stroke at this time. A systematic review assessed available efficacy data from three clinical trials (n = 496) of edaravone IV for acute ischemic stroke.¹³ These trials compared edaravone IV 30 mg twice daily for 14 days + another treatment vs. the other treatment alone within 72 hours of stroke symptom onset. One trial did not find significantly reduced mortality with edaravone IV vs. the control group; the other two studies did not report this endpoint. Overall, there was a significantly higher proportion of patients who had neurologic improvement in the edaravone IV group vs. control.

Coding Information

Note: 1) This list of codes may not be all-inclusive.
 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

HCPCS Codes	Description
J1301	Injection, edaravone, 1 mg

References

1. Radicava® intravenous infusion and Radicava® ORS® oral suspension [prescribing information]. Jersey City, NJ: Mitsubishi Tanabe; November 2022.
2. Abe K, Aoki M, Tsuji S, et al. on behalf of the edaravone (MCI-186) ALS 19 study group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. *Lancet Neurol.* 2017;16:505-512.
3. Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. *Amyotroph Lateral Scler Frontotemporal Degener.* 2014;15(7-8):610-617.
4. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). *Neurology.* 2009;73(15):1227-1233.
5. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). *Neurology.* 2009;73:1218-1226.
6. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. *Eur J Neurol.* 2012;19(3):360-375.
7. Munakata A, Ohkuma H, Nakano T, et al. Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery.* 2009;64(3):423-428.
8. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. *Circ J.* 2006;70(7):832-837.
9. Tang Y, Rong X, Hu W, et al. Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. *J Neurooncol.* 2014;120(2):441-447.

10. Maeno T, Tano R, Takenaka H, et al. Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular edema associated with branch retinal vein occlusion. *Br J Ophthalmol*. 2009;93(11):1479-1482.
11. Sano H, Kamijo T, Ino T, et al. Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss. *Auris Nasus Larynx*. 2010;37(1):42-46.
12. Data on file. Radicava™ Product Dossier: Based on AMCP guidelines for formulary submission, version 2.1. MT Pharma America, Inc.; received June 14, 2017.
13. Feng S, Yang Q, Liu M, et al. Edaravone for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2011;12:CD007230.
14. Van Damme P, Al-Chalabi A, Andersen PM, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). *Eur J Neurol*. 2024 Jun;31(6):e16264.
15. Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. *PLOS ONE*. 2022 Jun 14;17(6):e0258614.

Revision Details

Summary of Changes	Review Date	Effective Date
New Policy.	4/23/2026	6/15/2026

The policy effective date is in force until updated or retired.

APPENDIX*

El Escorial criteria for the diagnosis of ALS were initially developed by the World Federation of Neurology (WFN) in 1990. In 1998, the WFN held a workshop for the Research Committee on Motor Neuron Diseases at the Airlie Conference Center in Virginia, which resulted in a revision of the guidelines in 2000. The pivotal study of edaravone IV references the El Escorial criteria updated by the WFN in 2000 (Airlie House). According to these guidelines, the diagnosis of ALS requires:

The presence of:

- Evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiological, or neuropathologic examination; AND
- Evidence of upper motor neuron (UMN) degeneration by clinical examination; AND
- Progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination.

Together with the absence of:

- Electrophysiological or pathological evidence of other disease processes that might explain the signs of LMN and/or UMN degeneration; AND
- Neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs.

Without pathological confirmation, the diagnosis of ALS may be categorized into levels of certainty using clinical assessment. The following terms are used to describe the categories of diagnostic certainty.

- **Clinically Definite ALS:** defined on clinical evidence alone by the presence of UMN, as well as LMN signs, in the bulbar region and at least two spinal regions or the presence of UMN and LMN signs in three spinal regions.
- **Clinically Probable ALS:** defined on clinical evidence alone by UMN and LMN signs in at least two regions with some UMN signs necessarily rostral to (above) the LMN signs.
- **Clinically Probable ALS – Laboratory-supported:** defined when clinical signs of UMN and LMN dysfunction are in only one region, or when UMN signs alone are present in one region, and LMN signs defined by electromyography criteria are present in at least two regions, with proper application of neuroimaging and clinical laboratory protocols to exclude other causes.
- **Clinically Possible ALS:** defined when clinical signs of UMN and LMN dysfunction are found together in only one region or UMN signs are found alone in two or more regions; or LMN signs are found rostral to UMN signs and the diagnosis of Clinically Probable ALS – Laboratory supported cannot be proven by evidence on clinical grounds in conjunction with electrodiagnostic, neurophysiologic, neuroimaging, or clinical laboratory studies. Other diagnoses must have been excluded to accept a diagnosis of Clinically Possible ALS.

*** This appendix is for reference; it is NOT intended that patients meet the above criteria for approval of edaravone IV.**

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.